Effects of serelaxin in subgroups of patients with acute heart failure: results from RELAX-AHF.

ABSTRACT:

Aim

Patients hospitalized for acute heart failure (AHF) differ with respect of many clinical characteristics which may influence their prognosis and response to treatment. We have assessed possible differences in the effects of serelaxin on dyspnoea relief, 60 Day outcomes and 180 Day mortality across patient subgroups in the RELAX-AHF trial.

Methods and results

Subgroups were based on pre-specified covariates (age, sex, race, geographic region, estimated glomerular filtration rate, time from presentation to randomization, baseline systolic blood pressure, history of diabetes, atrial fibrillation, ischaemic heart disease, cardiac devices, i.v. nitrates at randomization). Other covariates which may modify the efficacy of AHF treatment were also analysed. Subgroup analyses did

SUBMITTER: Metra M 

PROVIDER: S-EPMC3800849 | biostudies-literature | 2013 Oct

REPOSITORIES: biostudies-literature